<DOC>
	<DOCNO>NCT02193360</DOCNO>
	<brief_summary>The purpose study determine initial safety , tolerability pharmacodynamics CD40-antagonist Mab , FFP104 , subject PBC</brief_summary>
	<brief_title>Pilot Study FFP104 Dose Escalation PBC Subjects</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Liver Cirrhosis , Biliary</mesh_term>
	<criteria>Male female Age 18 75 year age inclusive time signing informed consent Established diagnosis PBC accord EASL criterion ( European Association Study Liver 2009 ) : A diagnosis PBC make confidence adult patient otherwise unexplained elevation ALP presence antimitochondrial antibody ( AMA≥1:40 ) , and/or AMA type M2 . A liver biopsy essential diagnosis PBC patient , allow activity stage disease assess . Having screen ALP serum level 1.67 5x ULN inclusive . Be stable dose ursodeoxycholic acid ( UDCA ) 1220 mg/kg/day least 3 month prior Screening intolerant UDCA opinion investigator ( UDCA least 8 week prior Screening ) . Are pregnant breast feed plan become pregnant father child study . Female subject ( childbearing potential ) must willing use two medically accept form contraception throughout study must willing submit pregnancy test ( ) . Male subject must agree use medically accept contraception method partner throughout study describe , unless prior vasectomy . Has ability communicate adequately study staff comply requirement entire study , help caregiver , applicable . Laboratory screen result alanine transaminase ( ALT ) &gt; 5x ULN aspartate transaminase ( AST ) &gt; 5x ULN Total bilirubin &gt; 2x ULN . Isolated bilirubin &gt; 2x ULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % Total white blood cell ( WBC ) &lt; 3000 cells/mm3 Absolute neutrophil count ( ANC ) &lt; 1500 cells/mm3 Platelet count &lt; 100,000/mm3 Prothrombin time ( international normalize ratio ( INR ) &gt; 1.2 Body mass index ( BMI ) ≥35 suspect relevant nonalcoholic fatty liver disease ( NAFLD ) base judgment Investigator screen Subject history , current viral hepatitis B C ( include hepatitis B surface antigen [ HBsAg ] , hepatitis B core antibody hepatitis C virus ( HCV ) antibody [ antiHCV ] positivity ) , positive HIV antibody screen time screen Recipients liver organ transplantation anticipate need orthotropic organ transplantation one year determine Mayo Risk Score Coexisting liver biliary disease , primary sclerosing cholangitis , choledocholithiasis , acute chronic hepatitis , autoimmune hepatitis , alcoholic liver disease , nonalcoholic steatohepatitis ( NASH ) , acute infection bile duct system gall bladder , history gastrointestinal bleeding ( secondary portal hypertension ) , cholangiocarcinoma diagnose suspect liver cancer Recurrent variceal hemorrhage , uncontrolled encephalopathy , ChildPugh Class B/C , Esophageal Varices , refractory ascites within previous 6 month Screening ( define date inform consent sign ) Have family history ( one first degree relative ) multiple thrombotic event personal history venous arterial thrombotic event include deep vein thrombosis , stroke , myocardial infarction , pulmonary embolus , peripheral arterial thromboembolic event Prohibited medication 6 month prior Screening : azathioprine , colchicine , cyclosporine , methotrexate , mycophenolate mofetil , pentoxifylline ; fenofibrate fibrates ; budesonide systemic corticosteroid ; potentially hepatotoxic drug ( include αmethyldopa , sodium valproic acid , isoniazid , nitrofurantoin ) Prohibited medication 12 month prior Screening : antibody immunotherapy direct interleukin cytokine chemokines Subjects recurrent bacterial infection ( judged Investigator ) within 6 month prior first dose FFP104 , active bacterial , fungal mycobacterial infection observe screening , recent episode infection require hospitalization treatment antibiotic ( within 3 month prior first dose ) History malignancy , exception resect basal cell carcinoma , squamous cell carcinoma skin , resect cervical atypia carcinoma situ Immunization live vaccine within 4 week Screening exception influenza vaccine plan immunisation within period study Known clinically significant cardiac disease ( e.g. , myocardial infarction stroke , unstable angina , claudication , etc . ) , evidence clinically significant electrocardiogram ( ECG ) abnormality within previous 12 month prior Screening Subjects evidence serious , significant , acute chronic medical psychiatric illness , judgment Investigator , could compromise subject safety , limit subject 's ability complete study , and/or compromise objective study History recent ( within 12 month study ) alcohol drug abuse Use immunosuppressive medication 4 week prior Screening Active tuberculosis ( TB ) past currently suspect TB presently receive treatment prophylactic therapy , positive TB test ( defined local biological requirement ) , significant abnormality chest Xray within 3 month prior Screening Subjects plan surgery study period undergone major surgery within 3 month prior Screening Known clinically significant allergy know hypersensitivity drug , opinion Investigator , may affect patient 's safety Known sensitivity component study drug previous sensitivity reaction clinically significant reaction intravenous medication biologic therapy Participated another clinical trial within past 30 day prior Screening , still within washout period previous clinical trial previously receive FFP104 ( PG102 ) ch5D12 study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Inflammation</keyword>
	<keyword>PBC</keyword>
</DOC>